MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

11.96 1.36

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.67

Max

12.11

Galvenie mērījumi
By Trading Economics
Ienākumi	1.4M 676K
Pārdošana	961K 18M
Dividenžu ienesīgums	0.48
Peļņas marža	3.67
Darbinieki	212
EBITDA	-3M 2.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+67.25% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.48% 2.45%
Nākamie ieņēmumi	2026. g. 9. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-139M 229M
Iepriekšējā atvēršanas cena	10.6
Iepriekšējā slēgšanas cena	11.96

Ziņu noskaņojums

By Acuity

50%

148 / 349 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. apr. 22:56 UTC

Galvenie ziņu notikumi

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

2026. g. 1. apr. 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

2026. g. 1. apr. 23:55 UTC

Tirgus saruna

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

2026. g. 1. apr. 23:43 UTC

Tirgus saruna

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

2026. g. 1. apr. 23:23 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

2026. g. 1. apr. 23:07 UTC

Peļņas

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

2026. g. 1. apr. 23:02 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

2026. g. 1. apr. 22:39 UTC

Peļņas

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

2026. g. 1. apr. 22:08 UTC

Tirgus saruna

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

2026. g. 1. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

2026. g. 1. apr. 21:31 UTC

Galvenie ziņu notikumi

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 1. apr. 20:38 UTC

Peļņas

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

2026. g. 1. apr. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

2026. g. 1. apr. 20:13 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Tender Offer To Acquire Arcellx >GILD

2026. g. 1. apr. 20:07 UTC

Tirgus saruna

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

2026. g. 1. apr. 20:07 UTC

Iegādes, apvienošanās, pārņemšana

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

67.25% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD 67.25%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

148 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.